Although some EGFR inhibitors (known as tyrosine kinase inhibitors, TKIs), such as gefitinib, were developed for cancer treatment in HCC, their clinical outcomes are unsatisfactory [9, 10]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.